David M Peereboom


Affiliation: Cleveland Clinic Foundation
Country: USA


  1. Peereboom D, Shepard D, Ahluwalia M, Brewer C, Agarwal N, Stevens G, et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol. 2010;98:93-9 pubmed publisher
    ..Erlotinib co administered with RT and temozolomide was not efficacious and had an unacceptable toxicity. ..
  2. Ahluwalia M, Chao S, Parsons M, Suh J, Wang D, Mikkelsen T, et al. Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery in patients with 1-3 newly diagnosed brain metastases. J Neurooncol. 2015;124:485-91 pubmed publisher
    ..Future trials should continue to explore the paradigm of secondary chemoprevention of BM after definitive local therapy. ..
  3. Peereboom D, Ahluwalia M, Ye X, Supko J, Hilderbrand S, Phuphanich S, et al. NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro Oncol. 2013;15:490-6 pubmed publisher
    ..Erlotinib and sorafenib have significant pharmacokinetic interactions that may negatively impact the efficacy of the combination regimen. ..
  4. Aly Z, Peereboom D. Combination of Radiotherapy and Targeted Agents in Brain Metastasis: An Update. Curr Treat Options Neurol. 2016;18:32 pubmed publisher
    ..Advances in targeted therapies combined with radiation therapy will most likely improve local control and hopefully the quality of life and survival of patients with brain metastasis. ..